Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1997 7
1998 23
1999 38
2000 51
2001 62
2002 60
2003 81
2004 89
2005 79
2006 93
2007 88
2008 94
2009 102
2010 88
2011 82
2012 71
2013 103
2014 97
2015 61
2016 69
2017 79
2018 101
2019 54
2020 72
2021 80
2022 75
2023 47
2024 51

Text availability

Article attribute

Article type

Publication date

Search Results

1,804 results

Results by year

Filters applied: . Clear all
Page 1
Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review.
Lo CWH, Pathadka S, Qin SX, Fung LWY, Yan VKC, Yiu HHE, Bloom CI, Wong ICK, Chan EWY. Lo CWH, et al. Eur Respir Rev. 2023 Sep 27;32(169):230079. doi: 10.1183/16000617.0079-2023. Print 2023 Sep 30. Eur Respir Rev. 2023. PMID: 37758273 Free PMC article. Review.
BACKGROUND: The United States Food and Drug Administration issued a black box warning on the mental health adverse effects of montelukast in 2020. Age-related effects on the risk of developing specific neuropsychiatric events in montelukast users remain largely unkn …
BACKGROUND: The United States Food and Drug Administration issued a black box warning on the mental health adverse effects of montelukast …
Montelukast.
Markham A, Faulds D. Markham A, et al. Drugs. 1998 Aug;56(2):251-6; discussion 257. doi: 10.2165/00003495-199856020-00010. Drugs. 1998. PMID: 9711449 Review.
Montelukast is a selective antagonist of the leukotriene D4 (LTD4) receptor. In patients with asthma, montelukast 5 to 250 mg/day attenuated LTD4-induced bronchoconstriction and, at a dosage of 10 mg, significantly reduced early and late airway response to allergen …
Montelukast is a selective antagonist of the leukotriene D4 (LTD4) receptor. In patients with asthma, montelukast 5 to 250 mg/ …
Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.
Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Mahatme MS, et al. Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. Indian J Pharmacol. 2016. PMID: 28066101 Free PMC article. Clinical Trial.

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was less in montelukast-levocetirizine group than in montelukast-fexofenadine group. CONCLUSION: The decrease in TNSS was more in

…

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was

…
beta2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk.
Liu B, Svenningsson P, Ludvigsson JF, Lundholm C, Wallin J, Larsson H, Sjölander A, Williams DM, Pedersen NL, Wirdefeldt K. Liu B, et al. Ann Neurol. 2023 May;93(5):1023-1028. doi: 10.1002/ana.26638. Epub 2023 Mar 23. Ann Neurol. 2023. PMID: 36897287
A 38% lower PD incidence was noted among high-dose montelukast users when restricted to PD registered as the primary diagnosis. INTERPRETATION: Overall, our data do not support inverse associations between beta2AR agonists, montelukast, and PD. …
A 38% lower PD incidence was noted among high-dose montelukast users when restricted to PD registered as the primary di …
Montelukast as a potential treatment for COVID-19.
McCarthy MW. McCarthy MW. Expert Opin Pharmacother. 2023 Apr;24(5):551-555. doi: 10.1080/14656566.2023.2192866. Epub 2023 Mar 19. Expert Opin Pharmacother. 2023. PMID: 36927284 Review.
INTRODUCTION: Montelukast is a leukotriene inhibitor that is widely used to treat chronic asthma and allergic rhinitis. ...This paper reviews what is known about montelukast, an inexpensive, well-tolerated, and widely available medication, and examines the rationale …
INTRODUCTION: Montelukast is a leukotriene inhibitor that is widely used to treat chronic asthma and allergic rhinitis. ...This paper …
Association and mechanism of montelukast on depression: A combination of clinical and network pharmacology study.
Yan J, Sun H, Xin X, Huang T. Yan J, et al. J Affect Disord. 2024 Sep 1;360:214-220. doi: 10.1016/j.jad.2024.05.130. Epub 2024 May 31. J Affect Disord. 2024. PMID: 38824963
Multivariable regression was used to evaluate the association between montelukast exposure and depression. Network pharmacology was conducted to identify the mechanisms of montelukast on depression. ...Network pharmacology was identified 69 key targets …
Multivariable regression was used to evaluate the association between montelukast exposure and depression. Network pharmacology …
A meta-analysis of montelukast for recurrent wheeze in preschool children.
Hussein HR, Gupta A, Broughton S, Ruiz G, Brathwaite N, Bossley CJ. Hussein HR, et al. Eur J Pediatr. 2017 Jul;176(7):963-969. doi: 10.1007/s00431-017-2936-6. Epub 2017 Jun 1. Eur J Pediatr. 2017. PMID: 28567533 Free PMC article. Review.
Meta-analyses of studies of intermittent montelukast showed no benefit in preventing episodes of wheeze (mean difference (MD) 0.07, 95% confidence interval (CI) -0.14 to 0.29; mean for montelukast 2.68 vs placebo 2.54 (p = 0.5)), reducing unscheduled medical attenda …
Meta-analyses of studies of intermittent montelukast showed no benefit in preventing episodes of wheeze (mean difference (MD) 0.07, 9 …
Montelukast and risk for antidepressant treatment failure.
Chung H, Hanken K, Gerke AK, Lund BC. Chung H, et al. J Psychosom Res. 2023 Jan;164:111075. doi: 10.1016/j.jpsychores.2022.111075. Epub 2022 Nov 9. J Psychosom Res. 2023. PMID: 36368225
OBJECTIVE: While implicated in causing depression, no studies have examined the impact of montelukast on antidepressant effectiveness. We examined whether existing montelukast therapy was associated with acute antidepressant treatment failure (objective 1), and whet …
OBJECTIVE: While implicated in causing depression, no studies have examined the impact of montelukast on antidepressant effectiveness …
Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator.
Chen Y, Wang X, Shi H, Zou P. Chen Y, et al. Viruses. 2022 Apr 21;14(5):861. doi: 10.3390/v14050861. Viruses. 2022. PMID: 35632604 Free PMC article.
Additionally, the results showed that montelukast induced release of HCoV-OC43 genomic RNA by disrupting the integrity of the viral lipid membrane, and irreversibly inhibited viral infection. Considering the similarity among HCoV-OC43, MERS-CoV, and SARS-CoV-2, it suggests …
Additionally, the results showed that montelukast induced release of HCoV-OC43 genomic RNA by disrupting the integrity of the viral l …
Montelukast-induced generalized urticaria.
Minciullo PL, Saija A, Bonanno D, Ferlazzo E, Gangemi S. Minciullo PL, et al. Ann Pharmacother. 2004 Jun;38(6):999-1001. doi: 10.1345/aph.1D547. Epub 2004 Apr 27. Ann Pharmacother. 2004. PMID: 15113985
OBJECTIVE: To report a case of generalized urticaria induced by montelukast treatment. CASE SUMMARY: A 28-year-old man with allergic rhinitis and moderate persistent asthma developed generalized urticaria 5 days after the initiation of montelukast and inhaled flutic …
OBJECTIVE: To report a case of generalized urticaria induced by montelukast treatment. CASE SUMMARY: A 28-year-old man with allergic …
1,804 results